Eli Lilly (LLY) Debt to Equity (2009 - 2026)
Eli Lilly (LLY) reported Debt to Equity of $1.39 for Q1 2026, up 107.88% on a YoY basis from $0.67 in Q1 2025, and down 13.21% quarter-over-quarter from $1.6 in Q4 2025.
Eli Lilly (LLY) Debt to Equity (2009 - 2026) Analysis & Trends
Eli Lilly has reported Debt to Equity for 18 years, with the latest figure at $1.39 in Q1 2026.
- For the quarter ending Q1 2026, Debt to Equity rose 107.88% year-over-year to $1.39; the trailing twelve-month figure through Mar 2026 stood at $1.39 (up 107.88% YoY), and the FY2025 full-year result was $1.6, down 98.83% from the prior year.
- Debt to Equity for Q1 2026 stood at $1.39, down from $1.6 in the prior quarter.
- The five-year high for Debt to Equity was $393.09 in Q2 2024, with the low at -$720.29 in Q2 2025.
- Historically, Debt to Equity has averaged -$31.21 across 5 years, with a median of -$3.92 in 2022.
- Annual changes were most pronounced in 2022 — Debt to Equity jumped 4690.01% — and 2023, when it tumbled 12017.71%.
- Eli Lilly's Debt to Equity stood at $178.45 in 2022, then sank by 104.69% to -$8.37 in 2023, then surged by 1733.56% to $136.76 in 2024, then slumped by 98.83% to $1.6 in 2025, then slipped by 13.21% to $1.39 in 2026.
- The last three Debt to Equity figures came in at $1.39 (Q1 2026), $1.6 (Q4 2025), and $1.78 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn | - |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn | 1.39 |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn | 0.68 |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn | -9.70 |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn | 1.07 |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn | 6.24 |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn | 0.94 |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn | 0.72 |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn | 2.22 |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 |
| Dec 31, 2025 | 1.60 |
| Sep 30, 2025 | 1.78 |
| Jun 30, 2025 | -720.29 |
| Mar 31, 2025 | -17.65 |
| Dec 31, 2024 | 136.76 |
| Sep 30, 2024 | -16.52 |
| Jun 30, 2024 | 393.09 |
| Mar 31, 2024 | -6.10 |
| Dec 31, 2023 | -8.37 |
| Sep 30, 2023 | -448.18 |
| Jun 30, 2023 | -9.98 |
| Mar 31, 2023 | -5.00 |
| Dec 31, 2022 | 178.45 |
| Sep 30, 2022 | -3.70 |
| Jun 30, 2022 | -3.92 |
| Mar 31, 2022 | -3.91 |
| Dec 31, 2021 | -3.89 |
| Sep 30, 2021 | -3.83 |
| Jun 30, 2021 | 1.94 |